Enhanced complement activation and MAC formation accelerates severe COVID-19.
C3
Cd59
Complement
Endothelial dysfunction
MAC
Severe COVID-19
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
received:
10
05
2024
accepted:
26
08
2024
revised:
31
07
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
epublish
Résumé
Emerging evidence indicates that activation of complement system leading to the formation of the membrane attack complex (MAC) plays a detrimental role in COVID-19. However, their pathogenic roles have never been experimentally investigated before. We used three knock out mice strains (1. C3
Identifiants
pubmed: 39284944
doi: 10.1007/s00018-024-05430-w
pii: 10.1007/s00018-024-05430-w
doi:
Substances chimiques
Complement Membrane Attack Complex
0
CD59 Antigens
0
Complement C3
0
Complement C5
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
405Subventions
Organisme : NIH HHS
ID : P51OD011104-62
Pays : United States
Organisme : NIH HHS
ID : R01DK129881
Pays : United States
Organisme : NIH HHS
ID : R01HL165265
Pays : United States
Organisme : NIH HHS
ID : HL139930
Pays : United States
Organisme : American Heart Association
ID : AHA962950
Organisme : U.S. Department of Veterans Affairs
ID : IK6BX005235
Informations de copyright
© 2024. The Author(s).
Références
Xiao MT, Ellsworth CR, Qin X (2024) Emerging role of complement in COVID-19 and other respiratory virus diseases. Cell Mol Life Sci 81(1):94
pubmed: 38368584
pmcid: 10874912
doi: 10.1007/s00018-024-05157-8
Yan B, Freiwald T, Chauss D, Wang L, West E, Mirabelli C et al (2021) SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci Immunol. https://doi.org/10.1126/sciimmunol.abg0833
doi: 10.1126/sciimmunol.abg0833
pubmed: 34932384
pmcid: 8902698
Hess C, Kemper C (2016) Complement-mediated regulation of metabolism and basic cellular processes. Immunity 45(2):240–254
pubmed: 27533012
pmcid: 5019180
doi: 10.1016/j.immuni.2016.08.003
Van Damme KFA, Hoste L, Declercq J, De Leeuw E, Maes B, Martens L et al (2023) A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19. Sci Transl Med 15(710):eadi0252
pubmed: 37611083
doi: 10.1126/scitranslmed.adi0252
Qin X, Gao B (2006) The complement system in liver diseases. Cell Mol Immunol 3(5):333–340
pubmed: 17092430
Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13(9):954–966
pubmed: 18779537
doi: 10.1634/theoncologist.2008-0089
Morgan BP, Harris CL (1999) Complement regulatory proteins. Academic Press, London
Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M et al (2004) Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 53(10):2653–2661
pubmed: 15448097
doi: 10.2337/diabetes.53.10.2653
Acosta J, Qin X, Halperin J (2004) Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 10(2):203–211
pubmed: 14754399
doi: 10.2174/1381612043453441
Walport MJ (2001) Complement. First of two parts. N Engl J Med 344(14):1058–66
pubmed: 11287977
doi: 10.1056/NEJM200104053441406
Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344(15):1140–4
pubmed: 11297706
doi: 10.1056/NEJM200104123441506
Carney DF, Lang TJ, Shin ML (1990) Multiple signal messengers generated by terminal complement complexes and their role in terminal complexes elimination. J Immunol 145:621–629
doi: 10.4049/jimmunol.145.2.623
Papadimitriou JC, Ramm LE, Drachenberg CB, Trump BF, Shin ML (1991) Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b–9. J Immunol 147(1):212–217
pubmed: 1904901
doi: 10.4049/jimmunol.147.1.212
Niculescu F, Rus H, van Biesen T, Shin ML (1997) Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J Immunol 158(9):4405–4412
pubmed: 9127005
doi: 10.4049/jimmunol.158.9.4405
Niculescu F, Rus H (1999) Complement activation and atherosclerosis. Mol Immunol 36(13–14):949–955
pubmed: 10698349
doi: 10.1016/S0161-5890(99)00117-0
Niculescu F, Badea T, Rus H (1999) Sublytic C5b–9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 142(1):47–56
pubmed: 9920505
doi: 10.1016/S0021-9150(98)00185-3
Niculescu F, Rus H (2004) The role of complement activation in atherosclerosis. Immunol Res 30(1):73–80
pubmed: 15258311
doi: 10.1385/IR:30:1:073
Hila S, Soane L, Koski CL (2001) Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD. Glia 36(1):58–67
pubmed: 11571784
doi: 10.1002/glia.1095
Soane L, Cho HJ, Niculescu F, Rus H, Shin ML (2001) C5b–9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol 167(4):2305–2311
pubmed: 11490019
doi: 10.4049/jimmunol.167.4.2305
Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H (2006) C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281(28):19009–19018
pubmed: 16670089
doi: 10.1074/jbc.M602055200
Benzaquen LR, Nicholson-Weller A, Halperin JA (1994) Terminal complement proteins C5b–9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179(3):985–992
pubmed: 8113689
doi: 10.1084/jem.179.3.985
Nicholson-Weller A, Halperin JA (1993) Membrane signaling by complement C5b–9, the membrane attack complex. Immunol Res 12(3):244–257
pubmed: 8288945
doi: 10.1007/BF02918256
Sugita Y, Tobe T, Oda E, Tomita M, Yasukawa K, Yamaji N et al (1989) Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J Biochem (Tokyo) 106(4):555–557
pubmed: 2606909
doi: 10.1093/oxfordjournals.jbchem.a122893
Barratt-Due A, Pettersen K, Børresdatter-Dahl T, Holter JC, Grønli RH, Dyrhol-Riise AM et al (2024) Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients. J Intern Med. https://doi.org/10.1111/joim.13783
doi: 10.1111/joim.13783
pubmed: 38539241
Stenmark KR, Frid MG, Gerasimovskaya E, Zhang H, McCarthy MK, Thurman JM et al (2021) Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement. Pulm Circ 11(2):20458940211015800
pubmed: 34046161
pmcid: 8138299
doi: 10.1177/20458940211015799
Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA (2020) Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136(18):2080–2089
pubmed: 32877502
doi: 10.1182/blood.2020008248
Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P et al (2020) Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 130(11):6151–6157
pubmed: 32759504
pmcid: 7598040
doi: 10.1172/JCI141374
Chouaki Benmansour N, Carvelli J, Vivier E (2021) Complement cascade in severe forms of COVID-19: recent advances in therapy. Eur J Immunol 51(7):1652–1659
pubmed: 33738806
pmcid: 8250085
doi: 10.1002/eji.202048959
de Nooijer AH, Grondman I, Janssen NAF, Netea MG, Willems L, van de Veerdonk FL et al (2021) Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes. J Infect Dis 223(2):214–224
pubmed: 33038254
doi: 10.1093/infdis/jiaa646
Carvelli J, Demaria O, Vely F, Batista L, Chouaki Benmansour N, Fares J et al (2020) Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature 588(7836):146–150
pubmed: 32726800
pmcid: 7116884
doi: 10.1038/s41586-020-2600-6
Ma L, Sahu SK, Cano M, Kuppuswamy V, Bajwa J, McPhatter J et al (2021) Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol. https://doi.org/10.1126/sciimmunol.abh2259
doi: 10.1126/sciimmunol.abh2259
pubmed: 34623902
pmcid: 8158979
Qin Z, Liu F, Blair R, Wang C, Yang H, Mudd J et al (2021) Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics 11(16):8076–8091
pubmed: 34335981
pmcid: 8315069
doi: 10.7150/thno.61810
Liu F, Han K, Blair R, Kenst K, Qin Z, Upcin B et al (2021) SARS-CoV-2 infects endothelial cells in vivo and in vitro. Front Cell Infect Microbiol 11:701278
pubmed: 34307198
pmcid: 8292147
doi: 10.3389/fcimb.2021.701278
Peffault de Latour R, Bergeron A, Lengline E, Dupont T, Marchal A, Galicier L et al (2020) Complement C5 inhibition in patients with COVID-19 - a promising target? Haematologica 105(12):2847–50
pubmed: 33256385
doi: 10.3324/haematol.2020.260117
Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR et al (2020) Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci 117(40):25018–25025
pubmed: 32943538
pmcid: 7547220
doi: 10.1073/pnas.2010540117
Sinkovits G, Mező B, Réti M, Müller V, Iványi Z, Gál J et al (2021) Complement overactivation and consumption predicts in-hospital mortality in SARS-CoV-2 infection. Front Immunol 12:663187
pubmed: 33841446
pmcid: 8027327
doi: 10.3389/fimmu.2021.663187
Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J et al (2020) Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature 588(7836):146–150
pubmed: 32726800
pmcid: 7116884
doi: 10.1038/s41586-020-2600-6
Rajamanickam A, Nathella PK, Venkataraman A, Dasan B, Putlibai S, Ahamed SF et al (2023) Levels of complement components in children with acute COVID-19 or multisystem inflammatory syndrome. JAMA Network Open 6(3):e231713-e
doi: 10.1001/jamanetworkopen.2023.1713
Savitt AG, Manimala S, White T, Fandaros M, Yin W, Duan H et al (2021) SARS-CoV-2 exacerbates COVID-19 pathology through activation of the complement and kinin systems. Front Immunol 12:767347
pubmed: 34804054
pmcid: 8602850
doi: 10.3389/fimmu.2021.767347
Macor P, Durigutto P, Mangogna A, Bussani R, De Maso L, D’Errico S et al (2021) Multiple-organ complement deposition on vascular endothelium in COVID-19 patients. Biomedicines 9(8):1003
pubmed: 34440207
pmcid: 8394811
doi: 10.3390/biomedicines9081003
Lo MW, Kemper C, Woodruff TM (2020) COVID-19: complement, coagulation, and collateral damage. J Immunol 205(6):1488–1495
pubmed: 32699160
doi: 10.4049/jimmunol.2000644
Morrison TE, Fraser RJ, Smith PN, Mahalingam S, Heise MT (2007) Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J Virol 81(10):5132–5143
pubmed: 17314163
pmcid: 1900244
doi: 10.1128/JVI.02799-06
Stoiber H, Speth C, Dierich MP (2003) Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 21:S77–S82
pubmed: 12763687
doi: 10.1016/S0264-410X(03)00203-2
Liu F, Dai S, Gordon J, Qin X (2014) Complement and HIV-I infection/HIV-associated neurocognitive disorders. J Neurovirol 20(2):184–198
pubmed: 24639397
pmcid: 4251668
doi: 10.1007/s13365-014-0243-9
Soederholm A, Bánki Z, Wilflingseder D, Gassner C, Zwirner J, López-Trascasa M et al (2007) HIV-1 induced generation of C5a attracts immature dendriticcells and promotes infection of autologous T cells. Eur J Immunol 37(8):2156–2163
pubmed: 17595678
doi: 10.1002/eji.200636820
Stoiber H, Frank I, Spruth M, Schwendinger M, Mullauer B, Windisch JM et al (1997) Inhibiton of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol 34(12):855–863
pubmed: 9464521
doi: 10.1016/S0161-5890(97)00108-9
Yu Q, Yu R, Qin X (2010) The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol 7(5):334–340
pubmed: 20228834
pmcid: 4002684
doi: 10.1038/cmi.2010.8
Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR (1994) Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205(1):82–92
pubmed: 7526538
doi: 10.1006/viro.1994.1622
Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L et al (2021) Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: retrospective cohort study. PLoS One 16(12):e0261113
pubmed: 34928990
pmcid: 8687582
doi: 10.1371/journal.pone.0261113
Annane D, Heming N, Grimaldi-Bensouda L, Frémeaux-Bacchi V, Vigan M, Roux A-L et al (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 28:100590
pubmed: 33173853
pmcid: 7644240
doi: 10.1016/j.eclinm.2020.100590
Witzenrath M, Paassen P, Heunks L, Mourvillier B, de Bruin S, Lim E et al (2022) Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 10:1137–1146
pubmed: 36087611
pmcid: 9451499
doi: 10.1016/S2213-2600(22)00297-1
Skendros P, Germanidis G, Mastellos DC, Antoniadou C, Gavriilidis E, Kalopitas G et al (2022) Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. Sci Adv 8(33):eabo2341
pubmed: 35977025
pmcid: 9385148
doi: 10.1126/sciadv.abo2341
Qin X, Hu W, Song W, Grubissich L, Hu X, Wu G et al (2009) Generation and phenotyping of mCd59a and mCd59b double-knockout mice. Am J Hematol 84(2):65–70
pubmed: 19051264
pmcid: 4280255
doi: 10.1002/ajh.21319
Qin X, Hu W, Song W, Blair P, Wu G, Hu X et al (2009) Balancing role of nitric oxide in complement-mediated activation of platelets from mCd59a and mCd59b double-knockout mice. Am J Hematol 84(4):221–227
pubmed: 19229985
pmcid: 4280257
doi: 10.1002/ajh.21363
Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK et al (2009) Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 104(4):550–558
pubmed: 19131645
pmcid: 4267695
doi: 10.1161/CIRCRESAHA.108.191361
Wu G, Chen T, Shahsafaei A, Hu W, Bronson RT, Shi GP et al (2010) Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation 121(11):1338–1346
pubmed: 20212283
pmcid: 3057574
doi: 10.1161/CIRCULATIONAHA.108.844589
Wong L-YR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ et al (2022) Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605(7908):146–51
pubmed: 35314834
pmcid: 9783543
doi: 10.1038/s41586-022-04630-3
Ellsworth CR, Wang C, Katz AR, Chen Z, Islamuddin M, Yang H et al (2024) Natural killer cells do not attenuate a mouse-adapted SARS-CoV-2-induced disease in rag2−/− mice. Viruses 16(4):611
pubmed: 38675952
pmcid: 11054502
doi: 10.3390/v16040611
Han K, Blair RV, Iwanaga N, Liu F, Russell-Lodrigue KE, Qin Z et al (2021) Lung expression of human angiotensin-converting enzyme 2 sensitizes the mouse to SARS-CoV-2 infection. Am J Respir Cell Mol Biol 64(1):79–88
pubmed: 32991819
pmcid: 7781002
doi: 10.1165/rcmb.2020-0354OC
Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M et al (2007) The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci 27(29):7663–7672
pubmed: 17634361
pmcid: 6672891
doi: 10.1523/JNEUROSCI.5623-06.2007
Götz P, Azubuike-Osu SO, Braumandl A, Arnholdt C, Kübler M, Richter L et al (2022) Cobra venom factor boosts arteriogenesis in mice. Int J Mol Sci. 23(15):8454
pubmed: 35955584
pmcid: 9368946
doi: 10.3390/ijms23158454
Wang C, Khatun MS, Zhang Z, Allen MJ, Chen Z, Ellsworth CR et al (2023) COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes. Commun Biol 6(1):1265
pubmed: 38092883
pmcid: 10719262
doi: 10.1038/s42003-023-05626-z
Wang C, Khatun MS, Ellsworth CR, Chen Z, Islamuddin M, Nisperuza Vidal AK, Alam MA, Liu S, Mccombs JE, Maness NJ, Blair RV, Kolls JK, Qin X (2024) Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production. Commun Biol. In press
Powell MB, Marchbank KJ, Rushmere NK, van den Berg CW, Morgan BP (1997) Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol 158:1692–1702
pubmed: 9029105
doi: 10.4049/jimmunol.158.4.1692
Qian YM, Qin X, Miwa T, Sun X, Halperin JA, Song WC (2000) Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol 165(5):2528–2534
pubmed: 10946279
doi: 10.4049/jimmunol.165.5.2528
Baalasubramanian S, Harris CL, Donev RM, Mizuno M, Omidvar N, Song WC et al (2004) CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol 173(6):3684–3692
pubmed: 15356114
doi: 10.4049/jimmunol.173.6.3684
Qin X, Dobarro M, Bedford SJ, Ferris S, Miranda PV, Song W et al (2005) Further characterization of reproductive abnormalities in mCd59b knockout mice: a potential new function of mCd59 in male reproduction. J Immunol 175(10):6294–6302
pubmed: 16272280
doi: 10.4049/jimmunol.175.10.6294
Qin X, Miwa T, Aktas H, Gao M, Lee C, Qian YM et al (2001) Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mamm Genome 12(8):582–589
pubmed: 11471050
doi: 10.1007/s00335-001-2060-8
Qin X, Dobarro M, Bedford SJ, Ferris S, Miranda PV, Song W et al (2005) Further characterization of reproductive abnormalities in mCd59b knockout mice: a potential new function of mCd59 in male reproduction1. J Immunol 175(10):6294–6302
pubmed: 16272280
doi: 10.4049/jimmunol.175.10.6294
Qin X, Ferris S, Hu W, Guo F, Ziegeler G, Halperin JA (2006) Analysis of the promoters and 5’-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes. Genes Immun 7(4):287–297
pubmed: 16541098
doi: 10.1038/sj.gene.6364296
Al-Ani F, Chin-Yee I, Lazo-Langner A (2016) Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. Ther Clin Risk Manag 12:1161–1170
pubmed: 27536121
pmcid: 4975135
doi: 10.2147/TCRM.S96720
Mohebbi A, Haybar H, Nakhaei Moghaddam F, Rasti Z, Vahid MA, Saki N (2023) Biomarkers of endothelial dysfunction are associated with poor outcome in COVID-19 patients: a systematic review and meta-analysis. Rev Med Virol 33(4):e2442
pubmed: 36943015
doi: 10.1002/rmv.2442
Kotimaa J, Klar-Mohammad N, Gueler F, Schilders G, Jansen A, Rutjes H et al (2016) Sex matters: systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components. Mol Immunol 76:13–21
pubmed: 27337595
doi: 10.1016/j.molimm.2016.06.004
Wu M, Rowe JM, Fleming SD (2021) Complement initiation varies by sex in intestinal ischemia reperfusion injury. Front Immunol 12:649882
pubmed: 33868287
pmcid: 8047102
doi: 10.3389/fimmu.2021.649882
Wang C, Khatun MS, Zhang Z, Allen MJ, Chen Z, Ellsworth CR et al (2023) COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes. Commun Biol 6(1):1265
pubmed: 38092883
pmcid: 10719262
doi: 10.1038/s42003-023-05626-z
Zhou Y, Lu K, Pfefferle S, Bertram S, Glowacka I, Drosten C et al (2010) A Single Asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol 84(17):8753–8764
pubmed: 20573835
pmcid: 2919028
doi: 10.1128/JVI.00554-10
Hamed ME, Naeem A, Alkadi H, Alamri AA, AlYami AS, AlJuryyan A et al (2021) Elevated expression levels of lung complement anaphylatoxin, neutrophil chemoattractant chemokine IL-8, and RANTES in MERS-CoV-infected patients: predictive biomarkers for disease severity and mortality. J Clin Immunol 41(7):1607–1620
pubmed: 34232441
pmcid: 8260346
doi: 10.1007/s10875-021-01061-z
Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR et al (2018) Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. https://doi.org/10.1128/mBio.01753-18
doi: 10.1128/mBio.01753-18
pubmed: 30301856
pmcid: 6178621
Liu J, Li Y, Liu Q, Yao Q, Wang X, Zhang H et al (2021) SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov 7(1):17
pubmed: 33758165
pmcid: 7987126
doi: 10.1038/s41421-021-00249-2
Bösmüller H, Matter M, Fend F, Tzankov A (2021) The pulmonary pathology of COVID-19. Virchows Arch 478(1):137–150
pubmed: 33604758
pmcid: 7892326
doi: 10.1007/s00428-021-03053-1
Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M et al (2020) COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol 33(11):2156–2168
pubmed: 32879413
pmcid: 7463226
doi: 10.1038/s41379-020-00661-1
Datta PK, Liu F, Fischer T, Rappaport J, Qin X (2020) SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics 10(16):7448–7464
pubmed: 32642005
pmcid: 7330865
doi: 10.7150/thno.48076
Mikhaleva L, Chernayev A, Samsonova M, Zayratyants O, Kakturskiy L, Vasyukova O et al (2021) Pathological features in 100 deceased patients with COVID-19 in correlation with clinical and laboratory data. Pathol Oncol Res. https://doi.org/10.3389/pore.2021.1609900
doi: 10.3389/pore.2021.1609900
pubmed: 34421396
pmcid: 8376972
Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J (2020) A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol 33(11):2128–2138
pubmed: 32572155
pmcid: 7306927
doi: 10.1038/s41379-020-0603-3
Halperin JA, Taratuska A, Nicholson-Weller A (1993) Terminal complement complex C5b–9 stimulates mitogenesis in 3T3 cells. J Clin Investig 91(5):1974–1978
pubmed: 8486768
pmcid: 288194
doi: 10.1172/JCI116418
Li S, Zhang H, Li W, Zhai J, Li X, Zheng C (2024) The role of SARS-CoV-2 ORF7a in autophagy flux disruption: implications for viral infection and pathogenesis. Autophagy 20(6):1449–1451
pubmed: 38361390
doi: 10.1080/15548627.2024.2312787
Li S, Li X, Liang H, Yu K, Zhai J, Xue M et al (2023) SARS-CoV-2 ORF7a blocked autophagy flux by intervening in the fusion between autophagosome and lysosome to promote viral infection and pathogenesis. J Med Virol 95(11):e29200
pubmed: 37916857
doi: 10.1002/jmv.29200
Zhan Y, Ye L, Ouyang Q, Yin J, Cui J, Liu K et al (2023) The binding profile of SARS-CoV-2 with human leukocyte antigen polymorphisms reveals critical alleles involved in immune evasion. J Med Virol 95(9):e29113
pubmed: 37750416
doi: 10.1002/jmv.29113
Kumar J, Dhyani S, Kumar P, Sharma NR, Ganguly S (2023) SARS-CoV-2–encoded ORF8 protein possesses complement inhibitory properties. J Biol Chem 299(3):102930
pubmed: 36682494
pmcid: 9851726
doi: 10.1016/j.jbc.2023.102930
Ville S, Le Bot S, Chapelet-Debout A, Blancho G, Fremeaux-Bacchi V, Deltombe C et al (2021) Atypical HUS relapse triggered by COVID-19. Kidney Int 99(1):267–268
pubmed: 33188793
doi: 10.1016/j.kint.2020.10.030
Kaufeld J, Reinhardt M, Schröder C, Bräsen JH, Wiech T, Brylka P et al (2021) Atypical hemolytic and uremic syndrome triggered by infection with SARS-CoV2. Kidney Int Rep 6(10):2709–2712
pubmed: 34258481
pmcid: 8265210
doi: 10.1016/j.ekir.2021.07.004
Otieno SB, Altahan A, Kaweeta F, Karri S, Alnoor F, Johnson R (2021) Severe hemolysis in a COVID-19 patient with paroxysmal nocturnal hemoglobinuria. Case Rep Hematol 2021:6619177
pubmed: 34306774
pmcid: 8285198
Hines A, Hakim N, Barrientos J (2021) COVID-19 infection presenting as paroxysmal nocturnal hemoglobinuria. Clin Case Rep 9(8):e04636
pubmed: 34457288
pmcid: 8380091
doi: 10.1002/ccr3.4636
Uwatoko R, Shindo M, Hashimoto N, Iio R, Ueda Y, Tatematsu Y et al (2023) Relapse of atypical hemolytic uremic syndrome triggered by COVID-19: a lesson for the clinical nephrologist. J Nephrol. https://doi.org/10.1007/s40620-023-01595-y
doi: 10.1007/s40620-023-01595-y
pubmed: 36877369
pmcid: 9986860